IOLCP212.00

IOL Chemicals and Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMOREPENLABFDCINNOVACAPORCHPHARMASENORESSANOFIGUJTHEMRPGLIFEMcap ₹6,223 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)108.0696.9090.2090.20
Receivable Days (DSO)80.6590.1894.9394.93
Payable Days (DPO)119.33114.89117.30107.94
Cash Conversion Cycle (days)69.3872.1967.8377.19
Working Capital Turnover3.813.844.314.70
Asset Turnover0.950.870.900.90
Cash Conversion (CFO/Net Income)2.161.771.561.56
CFO/EBITDA1.260.880.800.80
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.